Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2748-2753

  Eberstå, Sofia ^a   Sandén, Emma ^a   Fritzell, Sara ^a   Darabi, Anna ^a   Visse, Edward ^a   Siesjö, Peter ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

brain tumor; COX 2 inhibition; GM CSF; immunotherapy

Indexed keywords

CD45 ANTIGEN; CYCLOOXYGENASE 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PARECOXIB; PROSTAGLANDIN E2; VALDECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TREATMENT RESPONSE; TUMOR CELL LINE;

BRAIN TUMOR; COX-2 INHIBITION; GM-CSF; IMMUNOTHERAPY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; INTRAMOLECULAR OXIDOREDUCTASES; ISOXAZOLES; MICE; MICE, INBRED C57BL; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 84896390675     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28607     Document Type: Article

References (24)

1. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16: 2443-9.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 352: 987-96.
3. Clavreul A, Piard N, Tanguy JY, et al. Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas. J Clin Neurosci 2010; 17: 842-8.
4. Wheeler CJ, Black KL,. DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Inv Drug 2009; 18: 509-19.
5. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14: 3098-104.
6. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001; 61: 4375-81.
7. Hara A, Okayasu I,. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004; 108: 43-8.
8. Lalier L, Cartron PF, Pedelaborde F, et al. Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme. Oncogene 2007; 26: 4999-5009.
9. Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118: 5498-505.
10. Mahic M, Yaqub S, Johansson CC, et al. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006; 177: 246-54.
11. Baratelli F, Lin Y, Zhu L, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005; 175: 1483-90.
12. Mandapathil M, Szczepanski MJ, Szajnik M, et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010; 285: 27571-80.
13. Smith KE, Janelidze S, Visse E, et al. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma. Int J Cancer 2007; 120: 75-80.
14. Agarwalla P, Barnard Z, Fecci P, et al. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 2012; 35: 385-9.
15. Eberstal S, Badn W, Fritzell S, et al. Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors. Cancer Immunol Immunr 2012; 61: 1191-9.
16. Wang D, Dubois RN,. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-93.
17. Demasi M, Cleland LG, Cook-Johnson RJ, et al. Effects of hypoxia on monocyte inflammatory mediator production: dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis. J Biol Chem 2003; 278: 38607-16.
18. Fitzpatrick FA, Aguirre R, Pike JE, et al. The stability of 13,14-dihydro-15 keto-PGE2. Prostaglandins 1980; 19: 917-31.
19. Dembo G, Park SB, Kharasch ED,. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005; 102: 409-15.
20. Mehta V, Johnston A, Cheung R, et al. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clin Pharmacol Ther 2008; 83: 430-5.
21. Baker PE, Fahey JV, Munck A,. Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol 1981; 61: 52-61.
22. Najar M, Raicevic G, Boufker HI, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010; 264: 171-9.
23. Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009; 15: 633-40.
24. Yao C, Hirata T, Soontrapa K, et al. Prostaglandin E(2) promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase. Nat Commun 2013; 4: 1685.